Can MicroRNA's Predict Multicentricity in Breast Cancer?
NCT ID: NCT04516330
Last Updated: 2020-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
57 participants
INTERVENTIONAL
2014-02-28
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients
NCT04778202
Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma
NCT05151224
Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT07289282
Circulating miRNAs.
NCT01722851
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
NCT01198301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
unifocal breast cancer
patients having unifocal breast cancer
miRNA
miRNA's expressed in breast cancer
multicentric breast cancer
patients having multicentric breast cancer
miRNA
miRNA's expressed in breast cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
miRNA
miRNA's expressed in breast cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Having no other malignancy
3. Female patient
Exclusion Criteria
2. Under 18 years old
3. Male patient
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bezmialem Vakif University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yeliz Emine Ersoy
Assoc. Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bezmialem Vakif University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCBC-MIR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.